Head to head
Privia Health vs Veeva Systems
Side-by-side on the measures that matter, with a plain-English read. Full detail: PRVA · VEEV
PRVA
Privia Health
25.05+1.46%
1-year price shape — +11% over the period
Quant Rating C · 54/100
vs
VEEV
Veeva Systems
266.22+1.26%
1-year price shape — -2% over the period
Quant Rating C · 37/100
1-year performance, rebased to 100
Veeva Systems edges it on the scoreable measures. Veeva Systems trades cheapest on trailing earnings; Veeva Systems earns the most per share.
| PRVA | VEEV | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Health Information Services |
| Last price | 25.05 | 266.22 |
| Change today | +1.46% | +1.26% |
| 1-year return | +11.1% | -1.6% |
| Market cap | $3.20B | $43.10B |
| 52-week range | 18.92 – 28.82 | 148.05 – 325.99 |
| Valuation | ||
| P/E (TTM) | 96.35 | 43.64 |
| P/E percentile, own 5-yr range | 43rd | 14th |
| P/B | 3.92 | 5.80 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 0.18 | 5.44 |
| Net profit (TTM) | $23.00M | $880.78M |
| Revenue (TTM) | $2.43B | $3.46B |
| Provider revenue period date | 2026-09-29 | 2026-07-30 |
| Revenue growth (YoY) | +13.2% | +17.6% |
| Gross margin | 9.9% | 75.0% |
| Operating margin | 2.1% | 29.9% |
| Net margin | 1.4% | 29.3% |
| Free cash flow (TTM) | $108.07M | $1.67B |
| Provider cash-flow period date | 2026-09-29 | 2026-07-30 |
| Ownership & sentiment | ||
| Institutional ownership | 98.1% | 88.0% |
| Insider activity (12mo) | 12 buy / 38 sell | 25 buy / 22 sell |
| Short interest (% of float) | 3.1% | 2.4% |
| Analyst consensus | 83% buy / 17% hold (6) | 74% buy / 22% hold / 4% sell (23) |
| Analyst price target | $31 (+22%) | $320 (+20%) |
| StockVane view | ||
| StockVane Quant Rating | C (54) | C (37) |
| Company | ||
| Employees | 1,226 | 7,928 |
| Founded | 2007 | 2007 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.